Jesse's Journey Foundation

Defeat Duchenne. Change Lives.

News & Resources

Santhera Pharmaceuticals: Vamorlone Long-Term Data

On September 22, 2022, Santhera announced its publication of long-term data with vamorlone in Duchenne muscular dystrophy. This is data extended from their previously published 24-week data and continues to show a reduction in steroid associated safety issues such as stunting of growth, cushingoid appearance (rounded face), hirsutism (excessive hair growth), weight gain and behavioural […]


Catabasis Connection: September 2020

Catabasis has provided an update on how they’re preparing to share top-line results from the Phase 3 PolarisDMD trial. Click here to see the September 2020 – Catabasis Connection Edasalonexent: In Duchenne, the loss of dystrophin leads to chronic activation of NF-kB, which is a key driver of skeletal and cardiac muscle disease progression. By […]


COVID-19 and Duchenne

With the growing concerns regarding COVID-19 (“coronavirus”) across Canadian communities and the world, our hearts go out to all those who've been impacted. We also want to show our profound gratitude to the health care professionals and everyone on the front lines of this pandemic. Jesse's Journey is here to support the Duchenne community during [...]

Santhera Pharmaceuticals: New Licensing Agreement with ReveraGen Pharma

On September 2, 2020, Santhera announced their new licensing agreement with ReveraGen Pharma, the company up until now, responsible for vamorolone. This agreement offers Santhera the advantage of full control of vamorolone. It allows them to pursue the development, registration, and commercialization of this anti-inflammatory drug candidate more effectively and efficiently. Santhera remains committed to […]


NS Pharma: FDA grants accelerated approval for Viltepso (viltolarsen)

The FDA has granted accelerated approval for Viltepso (viltolarsen) injection for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene is amenable to exon 53 skipping. Click here to read the full press release. The early clinical data demonstrated an increase in dystrophin production that is reasonably […]


Jesse’s Journey: Brand Awareness Survey

As Jesse’s Journey moves forward with future marketing and communication initiatives, we want to know: What does the Jesse’s Journey "brand" mean to you? We ask that you share your thoughts by completing a short survey - only about 10 minutes -  which will help provide us with insights and direction that will enhance our [...]

Jesse’s Journey + Muscular Dystrophy Canada (MDC): Return to School Webinar

Jesse's Journey and Muscular Dystrophy Canada (MDC) were very pleased to join forces to share information on returning to school for children with neuromuscular disorders. Many parents, caregivers, and guardians face new and difficult choices about how their child will return to school in the fall, such as deciding between in-person, virtual learning and home [...]

Congratulations: Dr. Rudnicki Elected as Fellow of the Royal Society

Jesse’s Journey would like to congratulate Dr. Michael Rudnicki, Chief Scientific Officer of Satellos Bioscience and a Jesse’s Journey research funding recipient, for being elected as a Fellow of the Royal Society, the United Kingdom’s national academy of sciences. The Royal Society is the world’s oldest and most esteemed scientific institution founded in 1660 and […]


Solid Biosciences: Update on SGT-001 Phase 1/2 Clinical Trial

On July 24, 2020, Solid Biosciences announced an update on their phase 1/2 clinical trial on SGT-001, an investigational gene therapy under development for Duchenne. This trial is currently on hold due to some safety concerns, but patients enrolled are continuing to engage in study-related activities. Their clinical biomarker results presented at a recent scientific […]


Catabasis Connection: July 2020

Catabasis has provided an update on their “North Star Ambulatory Assessment in Duchenne Muscular Dystrophy” as presented at the Parent Project Muscular Dystrophy (PPMD) Conference in July 2020. Click here to see the July 2020 – Catabasis Connection Edasalonexent: In Duchenne, the loss of dystrophin leads to chronic activation of NF-kB, which is a key […]


Disclaimer: Jesse's Journey provides the above information as a potential resource for our visitors. We do not verify the accuracy or truth of third party information and cannot be responsible for the quality of the information or services provided by other organizations and mentioned on our website, nor do we endorse any service, product, treatment or therapy.